Insider transaction details
Chief Medical Officer David Malcom Rodman of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) executed a sale of 2,170 shares of the companys common stock at $27.38 per share on April 9, 2026, generating proceeds of $59,414, according to a Form 4 filed with the Securities and Exchange Commission.
The filing indicates the sale was carried out pursuant to a Rule 10b5-1 trading plan that Rodman established on October 6, 2025. On the same day Rodman also exercised options to acquire 2,170 shares at an exercise price of $16.00 per share, for an aggregate cost of $34,720. Those options are part of a stock option program whose vesting schedule provides for 25% of the award to vest on the first anniversary of the grant date, with the remaining portion vesting in 36 equal monthly installments.
Post-transaction ownership
Following the sale and option exercise, Rodman directly holds 76,140 shares of Mineralys Therapeutics.
Market context and valuation
The insider activity comes as MLYS stock has delivered a 95% return over the last year. The shares currently trade above an InvestingPro Fair Value estimate of $22.90, a disparity the filing notes could indicate the stock is trading at a premium to that valuation metric. For investors seeking a deeper dive into valuation and financial details, a Pro Research Report is referenced as available on InvestingPro.
Recent operating and analyst developments
Mineralys reported fourth-quarter 2025 results that beat EPS expectations, with a reported loss per share of -0.4 versus a forecast of -0.94. The earnings surprise was accompanied by commentary highlighting increased general and administrative expenses.
Analyst coverage shows divergent views: BofA Securities raised its price target for Mineralys to $51.00, citing progress in the clinical development of the company's lead candidate, lorundrostat, for uncontrolled hypertension. Stifel reiterated a Buy rating and set a $52.00 price target, noting the companys commercial preparations following the FDAs acceptance of its New Drug Application. By contrast, Jefferies trimmed its target to $30.00 and maintained a Hold rating, pointing to strategic uncertainties related to lorundrostat.
Management appointment
In addition to the trading and financial updates, Mineralys announced the appointment of Jeffrey Munsie as Chief Legal Officer. The company described Munsie as bringing nearly 25 years of legal experience in the biopharmaceutical industry.
What this means
The disclosed transactions document an insider sale completed under an established trading plan alongside option exercises that mirror the number of shares sold. The filings also leave clear the company is moving through clinical and regulatory milestones while facing scrutiny around costs and strategy from different sell-side analysts.
Note: This article reports facts disclosed in company filings and public analyst commentary. It does not offer investment advice.